Mutational screening of EXT1 and EXT2 genes in Polish patients with hereditary multiple exostoses
详细信息 查看全文
- 作者：Aleksander Jamsheer (1) (2)
Magdalena Socha (1)
Anna Sowińska-Seidler (1)
Kinga Telega (1)
Tomasz Trzeciak (3)
Anna Latos-Bieleńska (1) (2) - 关键词：EXT1 ; EXT2 ; Hereditary multiple exostoses ; Multiple osteochondromas ; Mutation ; Polish patients
- 刊名：Journal of Applied Genetics
- 出版年：2014
- 出版时间：May 2014
- 年：2014
- 卷：55
- 期：2
- 页码：183-188
- 全文大小：156 KB
- 参考文献：1. Ahn J, Ludecke HJ, Lindow S, Horton WA, Lee B, Wagner MJ, Horsthemke B, Wells DE (1995) Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (EXT1). Nat Genet 11(2):137-43 CrossRef
2. Baasanjav S, Jamsheer A, Kolanczyk M, Horn D, Latos T, Hoffmann K, Latos-Bielenska A, Mundlos S (2010) Osteopoikilosis and multiple exostoses caused by novel mutations in LEMD3 and EXT1 genes respectively - coincidence within one family. BMC Med Genet 11:110 CrossRef
3. Busse M, Feta A, Presto J, Wilén M, Gr?nning M, Kjellén L, Kusche-Gullberg M (2007) Contribution of EXT1, EXT2, and EXTL3 to heparan sulfate chain elongation. J Biol Chem 282(45):32802-2810 CrossRef
4. Cheung PK, McCormick C, Crawford BE, Esko JD, Tufaro F, Duncan G (2001) Etiological point mutations in the hereditary multiple exostoses gene EXT1: a functional analysis of heparan sulfate polymerase activity. Am J Hum Genet 69(1):55-6 CrossRef
5. Ciavarella M, Coco M, Baorda F, Stanziale P, Chetta M, Bisceglia L, Palumbo P, Bengala M, Raiteri P, Silengo M, Caldarini C, Facchini R, Lala R, Cavaliere ML, De Brasi D, Pasini B, Zelante L, Guarnieri V, D’Agruma L (2013) 20 novel point mutations and one large deletion in EXT1 and EXT2 genes: report of diagnostic screening in a large Italian cohort of patients affected by hereditary multiple exostosis. Gene 515(2):339-48 CrossRef
6. de Andrea CE, Hogendoorn PC (2012) Epiphyseal growth plate and secondary peripheral chondrosarcoma: the neighbours matter. J Pathol 226(2):219-28 CrossRef
7. Fokkema IF, Taschner PE, Schaafsma GC, Celli J, Laros JF, den Dunnen JT (2011) LOVD v. 2.0: the next generation in gene variant databases. Hum Mutat 32(5):557-63 CrossRef
8. Francannet C, Cohen-Tanugi A, Le Merrer M, Munnich A, Bonaventure J, Legeai-Mallet L (2001) Genotype-phenotype correlation in hereditary multiple exostoses. J Med Genet 38(7):430-34 CrossRef
9. Hennekam RC (1991) Hereditary multiple exostoses. J Med Genet 28(4):262-66 CrossRef
10. HGMD? Professional 2013.4. https://portal.biobase-international.com/. Accessed December 2013
11. Jennes I, Entius MM, Van Hul E, Parra A, Sangiorgi L, Wuyts W (2008) Mutation screening of EXT1 and EXT2 by denaturing high-performance liquid chromatography, direct sequencing analysis, fluorescence in situ hybridization, and a new multiplex ligation-dependent probe amplification probe set in patients with multiple osteochondromas. J Mol Diagn 10(1):85-2 CrossRef
12. Jennes I, Pedrini E, Zuntini M, Mordenti M, Balkassmi S, Asteggiano CG, Casey B, Bakker B, Sangiorgi L, Wuyts W (2009) Multiple osteochondromas: mutation update and description of the multiple osteochondromas mutation database (MOdb). Hum Mutat 30(12):1620-627 CrossRef
13. Jones KB (2011) Glycobiology and the growth plate: current concepts in multiple hereditary exostoses. J Pediatr Orthop 31(5):577-86 CrossRef
14. Le Merrer M, Legeai-Mallet L, Jeannin PM, Horsthemke B, Schinzel A, Plauchu H, Toutain A, Achard F, Munnich A, Maroteaux P (1994) A gene for hereditary multiple exostoses maps to chromosome 19p. Hum Mol Genet 3(5):717-22 CrossRef
15. McCormick C, Duncan G, Goutsos KT, Tufaro F (2000) The putative tumor suppressors EXT1 and EXT2 form a stable complex that accumulates in the Golgi apparatus and catalyzes the synthesis of heparan sulfate. Proc Natl Acad Sci U S A 97(2):668-73 CrossRef
16. Mertens F, Rydholm A, Kreicbergs A, Willén H, Jonsson K, Heim S, Mitelman F, Mandahl N (1994) Loss of chromosome band 8q24 in sporadic osteocartilaginous exostoses. Gene Chromosome Cancer 9(1):8-2 CrossRef
17. Porter DE, Lonie L, Fraser M, Dobson-Stone C, Porter JR, Monaco AP, Simpson AH (2004) Severity of disease and risk of malignant change in hereditary multiple exostoses. A genotype-phenotype study. J Bone Joint Surg Br 86(7):1041-046 CrossRef
18. Raskind WH, Conrad EU 3rd, Matsushita M, Wijsman EM, Wells DE, Chapman N, Sandell LJ, Wagner M, Houck J (1998) Evaluation of locus heterogeneity and EXT1 mutations in 34 families with hereditary multiple exostoses. Hum Mutat 11(3):231-39 CrossRef
19. Sarrión P, Sangorrin A, Urreizti R, Delgado A, Artuch R, Martorell L, Armstrong J, Anton J, Torner F, Vilaseca MA, Nevado J, Lapunzina P, Asteggiano CG, Balcells S, Grinberg D (2013) Mutations in the EXT1 and EXT2 genes in Spanish patients with multiple osteochondromas. Sci Rep 3:1346 CrossRef
20. Schmale GA, Conrad EU 3rd, Raskind WH (1994) The natural history of hereditary multiple exostoses. J Bone Joint Surg Am 76(7):986-92
21. Schouten JP, McElgunn CJ, Waaijer R, Zwijnenburg D, Diepvens F, Pals G (2002) Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res 30(12):e57 CrossRef
22. Shapiro F, Simon S, Glimcher MJ (1979) Hereditary multiple exostoses. Anthropometric, roentgenographic, and clinical aspects. J Bone Joint Surg Am 61(6A):815-24
23. Signori E, Massi E, Matera MG, Poscente M, Gravina C, Falcone G, Rosa MA, Rinaldi M, Wuyts W, Seripa D, Dallapiccola B, Fazio VM (2007) A combined analytical approach reveals novel EXT1/2 gene mutations in a large cohort of Italian multiple osteochondromas patients. Gene Chromosome Cancer 46(5):470-77 CrossRef
24. Stickens D, Clines G, Burbee D, Ramos P, Thomas S, Hogue D, Hecht JT, Lovett M, Evans GA (1996) The EXT2 multiple exostoses gene defines a family of putative tumour suppressor genes. Nat Genet 14(1):25-2 CrossRef
25. Vanita V, Sperling K, Sandhu HS, Sandhu PS, Singh JR (2009) Novel EXT1 and EXT2 mutations in hereditary multiple exostoses families of Indian origin. Genet Test Mol Biomark 13(1):43-9 CrossRef
26. Wicklund CL, Pauli RM, Johnston D, Hecht JT (1995) Natural history study of hereditary multiple exostoses. Am J Med Genet 55(1):43-6 CrossRef
27. Wuyts W, Van Hul W, Wauters J, Nemtsova M, Reyniers E, Van Hul EV, De Boulle K, de Vries BB, Hendrickx J, Herrygers I, Bossuyt P, Balemans W, Fransen E, Vits L, Coucke P, Nowak NJ, Shows TB, Mallet L, van den Ouweland AM, McGaughran J, Halley DJ, Willems PJ (1996) Positional cloning of a gene involved in hereditary multiple exostoses. Hum Mol Genet 5(10):1547-557 CrossRef
28. Wuyts W, Radersma R, Storm K, Vits L (2005) An optimized DHPLC protocol for molecular testing of the EXT1 and EXT2 genes in hereditary multiple osteochondromas. Clin Genet 68(6):542-47 CrossRef - 作者单位：Aleksander Jamsheer (1) (2)
Magdalena Socha (1)
Anna Sowińska-Seidler (1)
Kinga Telega (1)
Tomasz Trzeciak (3)
Anna Latos-Bieleńska (1) (2)
1. Department of Medical Genetics, Poznan University of Medical Sciences, Rokietnicka 8 Street, 60-806, Poznan, Poland
2. NZOZ Center for Medical Genetics GENESIS, Grudzieniec 4 Street, 60-601, Poznan, Poland
3. Department of Orthopedics and Traumatology, Poznan University of Medical Sciences, 28 Czerwca 1956 r. 135/147 Street, 61-545, Poznan, Poland - ISSN：2190-3883
文摘
Hereditary multiple exostoses (HME) also known as multiple osteochondromas represent one of the most frequent bone tumor disorder in humans. Its clinical presentation is characterized by the presence of multiple benign cartilage-capped tumors located most commonly in the juxta-epiphyseal portions of long bones. HME are usually inherited in autosomal dominant manner, however de novo mutations can also occur. In most patients, the disease is caused by alterations in the EXT1 and EXT2 genes. In this study we investigated 33 unrelated Polish probands with the clinical and radiological diagnosis of HME by means of Sanger sequencing and MLPA for all coding exons of EXT1 and EXT2. We demonstrated EXT1 and EXT2 heterozygous mutations in 18 (54.6?%) and ten (30.3?%) probands respectively, which represents a total of 28 (84.9?%) index cases. Sequencing allowed for the detection of causative changes in 26 (78.8?%) probands, whereas MLPA showed intragenic deletions in two (6.1?%) further cases (15 mutations represented novel changes). Our paper is the first report on the results of exhaustive mutational screening of both EXT1/EXT2 genes in Polish patients. The proportion of EXT1/EXT2 mutations in our group was similar to other Caucasian cohorts. However, we found that EXT1 lesions in Polish patients cluster in exons 1 and 2 (55.6?% of all EXT1 mutations). This important finding should lead to the optimization of cost-effectiveness rate of HME diagnostic testing. Therefore, the diagnostic algorithm for HME should include EXT1 sequencing (starting with exons 1-), followed by EXT2 sequencing, and MLPA/qPCR for intragenic copy number changes.